Increased morning cortisol after ketamine treatment for suicidal depression: Exploratory report from a randomized trial.

J Affect DisordJun 25, 2026 (epub)
Clinical ResearchPsychiatryOpen access

Tse-Hwei Choo, Hanga C Galfalvy, John G Keilp et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial explored the effects of subanesthetic intravenous ketamine on morning cortisol levels in patients with suicidal depression. The study found a significant increase in waking cortisol levels 24 hours post-treatment (t(61) = -3.15, p = 0.0025), suggesting a potential link between cortisol response and treatment effects.

Key findings

  • A significant increase in waking cortisol was observed 24 hours after ketamine treatment (t(61) = -3.15, p = 0.0025).
  • The correlation between cortisol increase and decrease in suicidal ideation was small to medium and nonsignificant (r = -0.25, p = 0.052).

Why it matters

Understanding the relationship between cortisol levels and treatment response in suicidal depression may inform future therapeutic strategies and enhance resilience to stress, which is crucial for patient recovery.

Source

PubMed · PMID 42349524Free full text on PubMed Central

Published in J Affect Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.